API Holdings, the parent company of online pharmacy unicorn PharmEasy, is turning once again to debt markets to manage its obligations. The company announced that it will raise
API Holdings, the parent company of online pharmacy unicorn PharmEasy, is turning once again to debt markets to manage its obligations. The company announced that it will raise Rs 1,700 crore ($193 million) through redeemable non-convertible debentures (NCDs), pledging the shares of its listed subsidiary Thyrocare Technologies to secure the deal.
The proceeds from this fresh round of borrowing will be used to repay earlier debt obligations, offering temporary relief to the highly leveraged health-tech player.
According to exchange filings, API Holdings has issued 1,700 NCDs at Rs 10 lakh each, raising a total of Rs 1,700 crore. The latest instrument has been structured by pledging up to 61% of Thyrocare shares, which will be locked as collateral.
Previously, PharmEasy had issued NCDs with a total redemption value of Rs 1,820 crore. Out of this, Rs 1,545.4 crore remained outstanding, backed by the pledge of Docon Technologies’ 71.06% stake in Thyrocare. Following the repayment of that tranche, those shares will be released and re-pledged for the new issuance.
This refinancing maneuver ensures the company maintains control over its prized diagnostics subsidiary, which it had acquired in 2021.
The debt raise is led by 360 One, which alone contributed Rs 1,231 crore. Other participants include:
Eight additional investors—such as Kyrush Investments, Medley Pharmaceuticals, and Mahalaxmi Trust—subscribed to the remaining allotment.
This broad syndicate underlines continued investor willingness to fund PharmEasy, though through debt rather than equity.
This transaction marks PharmEasy’s third significant debt raise in four years, highlighting the company’s reliance on high-cost borrowings to sustain operations and manage earlier loans.
Although the company met repayment schedules, it reportedly breached some of Goldman’s restrictive covenants in mid-2023, further tightening its financial flexibility.
The debt raise comes at a time of significant leadership churn at API Holdings.
In August 2025, co-founder Siddharth Shah stepped down as chief executive officer, handing over reins to Rahul Guha, managing director and CEO of Thyrocare. Shah, however, continues to serve as director and vice chairman of API Holdings.
Earlier this year, other co-founders—Dharmil Sheth, Dhaval Shah, and Hardik Dedhia—exited executive positions to launch a new venture in the architecture and design space.
With the original founding team stepping back, institutional investors now wield greater influence over PharmEasy’s direction. Backers such as Ranjan Pai’s family office, Prosus, TPG, and Temasek are increasingly steering the company’s strategic and financial decisions.
PharmEasy was once hailed as one of India’s most promising digital health startups. The acquisition of Thyrocare in 2021 was seen as a landmark deal, positioning the company as a vertically integrated health-tech platform covering diagnostics, medicines, and teleconsultations.
However, the ambitious expansion has saddled the business with heavy debt, while profitability has remained elusive.
In this context, repeated debt raises signal the challenges of sustaining growth while servicing large financial obligations.
Thyrocare remains the crown jewel in PharmEasy’s portfolio. As a listed diagnostics firm with a nationwide presence, it provides steady revenue and asset value that lenders are comfortable backing.
By pledging Thyrocare shares, API Holdings is essentially leveraging its most valuable asset to buy time and manage repayments. Yet, this also underscores a risk: any prolonged inability to reduce debt could eventually threaten control over the subsidiary.
The fresh Rs 1,700 crore infusion buys PharmEasy some breathing room. It enables the company to close out the Goldman Sachs loan and reset its repayment cycle.
But fundamental questions remain:
Industry observers note that PharmEasy’s core business remains strong, with rising adoption of digital healthcare solutions in India. However, execution discipline and financial prudence will be critical in determining whether the unicorn can stabilize and return to growth without being weighed down by debt.
API Holdings’ decision to raise Rs 1,700 crore through NCDs is both a lifeline and a warning sign. While it demonstrates that investors are still willing to back the company, it also reflects a pattern of recurring high-cost debt that cannot be a permanent solution.
With a new leadership structure in place and institutional investors exerting control, PharmEasy stands at a crossroads. Success will depend on whether it can balance financial discipline, operational efficiency, and strategic clarity—all while navigating the increasingly competitive and regulated health-tech space in India.
